FUNCTIONAL AREAS – Page 34

Design space poorly justified during scale-up – how to ensure smooth tech transfer

When design space is inadequately justified during the scale-up phase, several signals may indicate underlying issues. It's essential to recognize these symptoms early to initiate timely interventions:Click to read the…

Process knowledge not captured during pilot scale – how to ensure smooth tech transfer

“`html Addressing Uncaptured Process Knowledge During Pilot Scale for Effective Tech Transfer In the pharmaceutical manufacturing environment, capturing comprehensive process knowledge during the pilot scale can often be overlooked, leading…

Excipient variability impact during comparability assessment – data package improvements for filing

Recognizing the signs of excipient variability is crucial for mitigating risks in drug development and manufacturing processes. Common indicators include:Click to read the full article.

Method development instability during comparability assessment – CAPA during development lifecycle

Identifying early signals of method development instability is crucial in mitigating potential impacts on the comparability assessment. Common symptoms to look out for include:Click to read the full article.

Design space poorly justified during transfer to manufacturing – downstream GMP risk and prevention

During manufacturing processes, various signals can indicate a poorly justified design space, which includes but is not limited to:Click to read the full article.

Method development instability during early development – regulatory scrutiny implications

Identifying early symptoms or signals of method development instability is crucial for timely intervention. Common indicators include:Click to read the full article.

Tech transfer readiness gaps during transfer to manufacturing – how to ensure smooth tech transfer

Detecting readiness gaps typically starts with the identification of specific symptoms or signals on the manufacturing floor or within laboratory settings. Some common indications include:Click to read the full article.

Process knowledge not captured during pilot scale – data package improvements for filing

The first step in addressing the issue of insufficient process knowledge involves identifying observable symptoms or signals on the manufacturing floor or in the laboratory environment. Common indicators include:Click to…

Method development instability during early development – CAPA during development lifecycle

Identifying symptoms of method development instability is crucial for mitigating risks and ensuring data integrity. Common signals may include:Click to read the full article.

Method development instability during pilot scale – regulatory scrutiny implications

Method development instability manifests through various symptoms that are critical for timely identification and intervention. Common signals include:Click to read the full article.

Formulation robustness underestimated during scale-up – how to ensure smooth tech transfer

Identifying the right signals and symptoms is crucial when dealing with formulation robustness issues during scale-up. Below are some common symptoms that may indicate potential problems in the formulation or…

Excipient variability impact during early development – regulatory scrutiny implications

Identifying symptoms of excipient variability is essential for maintaining product quality and compliance. Common signals include:Click to read the full article.